News Releases

Mar. 15, 2005

Announcement for Concluding License Agreement for "KGA-2727", a novel Agent for the treatment of diabetes

Kissei Pharmaceutical Co., Ltd. (President: Mutsuo Kanzawa) and Dainippon Pharmaceutical Co., Ltd. (President: Kenjiro Miyatake) announced today that they entered into a license agreement on "KGA-2727", a novel agent for the treatment of diabetes, which was discovered by Kissei.

Under this agreement, Dainippon obtains from Kissei the right for the development and marketing of "KGA-2727" in Japan, while Kissei receives from Dainippon an upfront payment and milestone payments at each stage of development.

"KGA-2727", discovered by Kissei, is a selective inhibitor for Na+-dependent glucose transporter (SGLT1) and an agent for treating diabetes with a novel mechanism of action, improving postprandial hyperglycemia by inhibiting glucose absorption in the gut. The effect of improving postprandial hyperglycemia for this agent has been confirmed in various animal models for diabetes, and the agent is expected to be a drug for diabetes with novel approach.

In future, Kissei will continue to conduct non-clinical studies while Dainippon will conduct clinical development and marketing in Japan. Kissei reserves the right to participate in the clinical development to be conducted by Dainippon as well as the right to co-market the agent.

Kissei continues to own the right for this agent outside Japan, including the right for development, manufacturing and marketing.

<<For reference>>
SGLT1 (Sodium-dependent Glucose Transporter 1):

This is one of the transporters involved in transporting glucose in the body. It exists in the small intestine abundantly and plays a major role for the glucose absorption in the gut. The SGLT1 inhibitor is expected to improve postprandial hyperglycemia by directly inhibiting the function of SGLT1 resulting in suppressing glucose absorption in the gut.
The -glucosidase inhibitors delay the glucose absorption after the meal by inhibiting the enzyme decomposing disaccharide in the small intestine resulting in suppressing the decomposition of disaccharide.